Record-setting attendance for the global pharmacometrics community
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
Simulations Plus' Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
DILIsym application contributes to approval of new drugs for migraine treatment
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions
Simulations Plus Successfully Delivers FDA-Funded Project
Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40%
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
Improving access to treatment in the lives of individuals and families affected by rare diseases
Simulations Plus Releases MembranePlus™ 3.0
New functionality for transdermal products creates a state-of-the-art IVIVE methodology in combination with the GastroPlus TCAT platform
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced...
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy,
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech